Nano-X Imaging Ltd. has announced that it has received FDA 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. The TAP2D feature provides radiologists with a 2D image generated directly from the tomosynthesis scan, enabling both 3D and 2D views from a single scan without additional radiation exposure to the patient. This regulatory clearance is part of Nanox's strategy to position its tomosynthesis systems as primary diagnostic solutions in the United States. The company plans to make the TAP2D enhancement available to existing installations as part of its ongoing rollout of imaging improvements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nano-X Imaging Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162763-en) on February 03, 2026, and is solely responsible for the information contained therein.